1 2

TIRZEPATIDE

REFERENCE STANDARD

Manufactured & Fulfilled in Wyoming, USA
Identity Verified • HPLC Tested • Lot Tracked • Research Use Only
VELORA RESEARCH ADVANTAGES
✓ Fresh Production Lots
✓ QR Traceability
✓ Domestic Fulfillment
✓ Direct Manufacturer Support
✓ Lot-Specific Documentation
✓ COA Available

Manufactured for Researchers Who Refuse to Compromise

Velora Biolabs manufactures, lyophilizes, packages, and fulfills research materials directly from our Wyoming laboratory.

Every production lot is assigned unique batch documentation, QR traceability, and lot-specific verification to support consistency and reproducibility.

Unlike suppliers relying on aging inventory and third-party fulfillment, Velora maintains direct oversight from production through shipment.

$69.00
$69.00
Specification

CURRENT LOT INVENTORY

Photographed inventory manufactured, packaged, and fulfilled directly by Velora Biolabs in Wyoming, USA.


✓ Fresh Production Lots

✓ QR Verification

✓ Batch Documentation

✓ Domestic Fulfillment

✓ Direct Manufacturer Support

LOT DOCUMENTATION

Scientific Background

Advanced Metabolic, Obesity & Insulin Sensitivity Research Peptide

Category:
Metabolic Research • Obesity Biology • Endocrine Signaling • Insulin Resistance

 

What Researchers Study

Tirzepatide is a synthetic dual-incretin peptide that simultaneously activates:

  • GLP-1 (Glucagon-Like Peptide-1) receptors

  • GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors

This dual mechanism allows researchers to study coordinated metabolic signaling, rather than isolated appetite suppression or insulin stimulation.

Tirzepatide is widely used as a reference compound for:

  • Advanced obesity models

  • Insulin resistance and diabetes research

  • Fat vs lean mass partitioning

  • Incretin synergy and receptor cross-talk

  • Comparative studies against GLP-1 mono-agonists (e.g., semaglutide)

 

Primary Signal Pathways Studied

  • GLP-1 receptor signaling

  • GIP receptor signaling

  • Pancreatic β-cell insulin secretion

  • Central appetite regulation

  • Peripheral insulin sensitivity

  • Adipocyte nutrient partitioning

  • Energy expenditure modulation

Tirzepatide enables study of dual incretin amplification, not achievable with GLP-1-only peptides.

 

Why This Molecule Matters in Research

GLP-1 agonists reduce appetite — but often plateau.
GIP alone can be obesogenic — but in combination, it becomes metabolically synergistic.

Tirzepatide demonstrates that:

  • GIP signaling reprograms adipose tissue

  • GLP-1 controls appetite and glycemia

  • Together, they produce greater fat loss, better insulin sensitivity, and improved metabolic flexibility

This makes tirzepatide a mechanistic bridge between:

  • Semaglutide (GLP-1 mono-agonist)

  • Retatrutide (GLP-1 + GIP + Glucagon triple agonist)

 

Mechanism of Action (Research Context)

GLP-1 Axis

  • Enhances glucose-dependent insulin secretion

  • Suppresses glucagon during hyperglycemia

  • Slows gastric emptying

  • Reduces central appetite signaling

GIP Axis

  • Improves insulin sensitivity in adipose tissue

  • Enhances nutrient uptake efficiency

  • Modulates fat storage vs oxidation

  • Alters adipokine signaling

Combined Effect

  • Greater body weight reduction than GLP-1 alone

  • Superior HbA1c and insulin sensitivity outcomes

  • Improved fat-to-lean mass ratio during weight loss

 

Key Research Domains

1. Obesity & Body Composition Research

Tirzepatide consistently demonstrates:

  • Greater total weight reduction than GLP-1 mono-agonists

  • Preferential loss of fat mass

  • Better lean mass preservation

Researchers frequently use tirzepatide as a control comparator in next-generation obesity peptide development.

2. Insulin Resistance & Glycemic Control

Tirzepatide is studied for:

  • Enhanced insulin secretion (glucose-dependent)

  • Improved peripheral insulin sensitivity

  • Reduced fasting glucose and HOMA-IR

  • β-cell functional preservation

Its dual incretin action allows deeper study of pancreatic–adipose communication.

3. Lipid & Hepatic Metabolism

Observed research effects include:

  • Reduced triglycerides

  • Improved LDL / HDL ratios

  • Decreased hepatic fat accumulation

  • Improved markers of NAFLD/NASH in animal models

4. Comparative Incretin Research

Tirzepatide is frequently compared against:

  • Semaglutide (GLP-1 only)

  • Liraglutide

  • Retatrutide (triple agonist)

This positions it as a benchmark peptide in metabolic signaling studies.

 

Research Application Guidelines

For experimental planning only — not for human or veterinary use.

Research Model Typical Range Route Study Focus
In-vitro 1–100 nM Cell media Receptor binding, insulin signaling
Rodent models 0.1–0.5 mg/kg SC Weight, glucose, insulin sensitivity
Primate models 0.05–0.15 mg/kg SC Body composition, glycemic control
Chronic studies Weekly dosing SC Long-term metabolic adaptation

 

Product Specifications

  • Compound Name: Tirzepatide

  • CAS Number: 2023788-19-2

  • Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

  • Molecular Weight: 4,813.53 Da

  • Peptide Class: Dual incretin receptor agonist

  • Purity: ≥98% (HPLC verified)

  • Form: Lyophilized powder

  • Appearance: White to off-white solid

 

Batch Documentation & Traceability

Each vial is shipped with a lot-specific QR code that provides secure access to batch documentation, including:

• Certificate of Analysis (COA)
• Identity verification report (HPLC / MS)
• Lot number, potency, and expiration

Documentation is locked to the specific batch shipped to ensure traceability, version control, and research reproducibility.

QR access is provided with the physical product and is not reused across lots.

 

Research Use Disclaimer

This product is supplied strictly for laboratory research use.
Not for human or veterinary consumption, diagnosis, or treatment.